Skip to main content

Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report



Immune checkpoint inhibitors are effective therapies for a wide range of malignancies. Their increased use has led to a wide range of immune-related adverse effects including skin, gastrointestinal, pulmonary, endocrine, cardiac, and neurologic complications.

Case presentation

We present the case of a 72-year-old Caucasian man with non-small cell lung cancer who was admitted for dyspnea after two cycles of durvalumab. He was found to have significantly elevated levels of serum creatinine kinase and troponin with a negative cardiac catheterization. During his hospitalization, he developed progressive dyspnea and new-onset axial weakness, ultimately leading to the diagnosis of durvalumab-induced myocarditis, myasthenia gravis, and myositis.


This is, to our knowledge, the first reported case of anti-programmed cell death ligand 1-induced combination of myocarditis, myasthenia gravis, and myositis. While the use of immunologic agents has resulted in overall improved cancer outcomes, their increased use has led to a vast spectrum of immune-related adverse effects. We review the diagnostic workup and management of patients with these immune-related adverse effects, underscoring the importance of early identification given the potential for rapid deterioration.

Peer Review reports


Durvalumab (MedImmune/AstraZeneca) is a human immunoglobulin G1 kappa monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). It has been demonstrated to have significant antitumor activity and is FDA-approved for use in non-small cell lung cancer and urothelial carcinoma. In March 2020, approval was added for durvalumab in combination with etoposide and either carboplatin or cisplatin as a first-line treatment of patients with extensive small cell lung cancer [1]. While immune checkpoint inhibitors (ICI) are now a mainstay of treatment for numerous malignancies, they are also associated with immune-related adverse effects (irAE). The most common irAE for durvalumab are immune-mediated dermatologic reactions (1.6%), colitis (1.6%), hepatitis (1%), nephritis (0.3%), and endocrinopathies including hypothyroidism (7.3%) and hyperthyroidism (1.4%), adrenal insufficiency (0.4%), type 1 diabetes mellitus (< 0.1%), and hypopituitarism/hypophysitis (< 0.1%). [1] Here, we present a patient who developed a rare combination of adverse effects: myocarditis, myositis, and myasthenia gravis, as a result of PD-L1 inhibition with durvalumab. 

Case presentation

A 72-year-old Caucasian man with a history of prostate cancer, central serous retinopathy, obstructive sleep apnea, type 2 diabetes mellitus, hypertension, and mild chronic obstructive pulmonary disease but no known coronary artery disease or history of neurologic disorders was first diagnosed with left lower lobe non-small cell lung cancer (NSCLC) in 2013, for which he underwent a left lower lobectomy that same year. On surveillance imaging in 2014, he was noted to have a right lower lobe nodule and was diagnosed with a second primary NSCLC, for which he underwent stereotactic body radiation therapy (SBRT). In 2017, he was noted to have an enlarging left upper lobe nodule that was treated with SBRT. Surveillance CT imaging in September 2018 was significant for an enlarging right upper lobe nodule with right paratracheal lymph node involvement. Subsequent positron emission tomography (PET)-CT revealed several FDG-avid mediastinal and right hilar nodes concerning for malignancy. Metastatic bronchogenic adenocarcinoma was confirmed via endobronchial ultrasound with transbronchial needle aspiration, with pathology showing 5/5 positive lymph nodes. PD-L1 immunohistochemistry 22C3 (Keytruda) testing of the lymph node revealed high PD-L1 expression with 80% tumor proportion score. MRI of the brain was negative for intracranial metastatic disease. He was diagnosed with TxN3M0 stage IIIB adenocarcinoma and was treated with six cycles of weekly cisplatin and SBRT. He then initiated adjuvant durvalumab for maintenance therapy, receiving two cycles (10 mg/kg) on treatment days 0 and 15. Our patient subsequently presented to the emergency department on day 18 with a 4-day history of shortness of breath, weakness, and chest pressure. Workup on admission was significant for lateral lead ST elevations with an initial troponin of 7.1 ng/dL. He emergently underwent a left heart catheterization, which was negative for obstructive coronary artery disease. Transthoracic echocardiogram was significant for a normal ejection fraction with mild left ventricular concentric hypertrophy.

Admission diagnosis was myopericarditis of unclear etiology. On hospital day 4, he was noted to have persistently elevated levels of serum troponin, peaking at 12 ng/mL. His levels of serum creatinine kinase (CK) were elevated as well, peaking at 9262 U/L. He had persistent mild hepatocellular transaminitis (peak AST 72, ALT 531). The use of corticosteroids was discussed with the patient owing to concern for irAE; however the patient declined on the basis of his central serous retinopathy. He was noted to have dysphagia on admission with regurgitation of solids and liquids. A barium swallow study and esophagogastroduodenoscopy on hospital day 3 did not reveal any structural abnormalities. On hospital day 9, the patient developed progressive axial weakness, with increasing difficulty holding his head upright while seated. Neurology was consulted, who had a high concern for myasthenic crisis, which was subsequently confirmed by decreased negative inspiratory forces and elevated acetylcholine receptor binding and blocking antibodies. Due to his declining respiratory status, he was transferred to the intensive care unit (ICU) and intubated on the same day for airway protection. MRI of the brain performed on hospital day 10 was significant for 12 new metastatic lesions with surrounding vasogenic edema. The patient was started on high-dose corticosteroids at 1 mg/kg/day and underwent plasmapheresis on hospital day 10, completing 5 rounds. Unfortunately, he was unable to be weaned from mechanical ventilation and required tracheostomy placement as well as percutaneous endoscopic gastrostomy nutrition.

After multiple goals-of-care discussions, the patient was transferred from the ICU to a long-term acute care facility owing to mechanical ventilation dependence, on hospital day 36. Diagnoses of myopericarditis, myositis, and myasthenic crisis were attributed to immune-mediated response to durvalumab.

Discussion and conclusions

The differential diagnosis for dyspnea and weakness is broad, but they may be the presenting symptoms for irAE in a patient on immunotherapy. This report presents an individual who developed a rare combination of adverse effects: myocarditis, myositis, and myasthenia gravis (MG) as a result of PD-L1 inhibition with durvalumab.

ICI-related myocarditis is a rare irAE with a reported incidence of 0.04–1.14% but is associated with a mortality of 25–50% [2]. Female patients, patients > 75 years old, and patients with concomitant use of other immune checkpoint inhibitors have been found to have significantly increased risk for myocarditis [3]. There is a wide spectrum of severity, ranging from asymptomatic elevation in cardiac enzyme levels to end organ dysfunction as categorized by the American Society of Clinical Oncology. This patient presented with ST elevation and marked elevation in cardiac enzyme levels, but was found to have no obstructive coronary artery disease, leading to the diagnosis of likely ICI-related myocarditis. First-line treatment relies on high-dose corticosteroids and immediate discontinuation of the offending agent. Second-line treatment options remain unproven, but include intravenous immunoglobulin, mycophenolate, infliximab, alemtuzumab, and abatacept [4]. Our patient had a relative contraindication to steroids due to his central serous retinopathy, but given his severe symptoms was ultimately treated with high-dose steroids and plasmapheresis.

Paraneoplastic neurologic syndromes such as Lambert-Eaton myasthenic syndrome (LEMS) have been clearly established to be associated with lung carcinoma. LEMS was considered upon development of respiratory failure; however, the patient had negative voltage-gated calcium channel antibodies, which would be inconsistent with the diagnosis. Myasthenia gravis as a paraneoplastic syndrome in primary lung carcinomas has not been clearly described in the literature; as such, it was thought that our patient’s myasthenic crisis arose from the ICI [5]. ICI-related MG is a rare irAE with a reported incidence of less than 1%. ICI-related MG often occurs between 2 and 6 weeks of initiation of checkpoint inhibitors. Thus, given the time course of symptoms, ICI-related MG is the more likely diagnosis. Compared with classical myasthenia gravis, which has a bimodal age distribution and female predominance, MG associated with immune checkpoint inhibitors seems to occur mostly in men, at a relatively older onset [6]. Two pathogenic autoantibodies are present in the majority of MG patients: 85% have anti-acetylcholine receptor autoantibodies (AchR), and 8% have anti-muscle-specific tyrosine kinase (MuSK) autoantibodies [7]. Our patient was found to have anti-AchR antibodies. In a large retrospective study of immunotherapy-induced MG by the anti-PD1 nivolumab, 8 of 12 patients developed severe symptoms including myasthenic crisis [8]. Onset of MG occurred early in their treatment course (within one or two treatments), and patients developed rapid progression, consistent with the clinical course of our patient. Prompt identification of this rare adverse event is imperative as respiratory support either through noninvasive positive pressure ventilation or mechanical ventilation may be necessary, given the potential for acute respiratory failure secondary to progressive MG. In patients with mild symptoms, pyridostigmine can be used, but in patients with severe symptoms and rapid progression, immunosuppression with intravenous methylprednisolone is required [4]. There is some evidence suggesting that intravenous immunoglobulin (IVIG) and plasma exchange as a first-line therapy may have better outcomes compared with steroids alone [9].

Finally, myositis can co-occur in patients who develop MG. In most reported cases, CK was significantly elevated, with reported levels ranging from 1200 to 8729 IU/L [10]. While muscle biopsy was not obtained in our patient and in most reported cases, the presence of elevated CK along with transaminases likely reflects muscle damage rather than hepatic injury as our patient had normal bilirubin and INR and unremarkable liver imaging. In an observational, retrospective study of patients with idiopathic MG and inflammatory myopathies, seven of eight patients had antistriational autoantibodies, and three of these patients also developed myocarditis [11]. This suggests there may be autoimmune targets with similar epitopes on heart and skeletal muscles. ICI-induced MG with antistriational antibodies has been associated with rapid progression and more severe outcomes, so early antibody screening may assist in prompt detection and prognostication of severe irAEs [11].

The combination of myocarditis, MG, and myositis has been reported with different ICI, including ipilimumab and nivolumab [12]. Myocarditis has been previously reported in patients treated with durvalumab, but this, to our knowledge, is the first reported case of anti-PD-L1-induced combination of myocarditis, myasthenia gravis, and myositis [13]. While ICIs have been touted to have an improved tolerability profile in comparison with chemotherapy, it is critical to be mindful of the wide range of tissues that can be affected by immune-mediated inflammation, with subsequent life-threatening organ failure. irAE are most common in the endocrine, skin, pulmonary, and gastrointestinal systems. However, treating physicians must be vigilant for less common immune diatheses, including neuropathic and myopathic syndromes such as the triad of myasthenia gravis, myocarditis, and myositis suffered by our patient. Here, we reviewed the principals of diagnosis and management of these rare but potentially fatal complications.

Availability of data and materials

The data supporting the findings of this study are available from the corresponding author upon reasonable request.



Programmed cell death ligand 1


Immune-related adverse event


Non-small cell lung cancer


Stereotactic body radiation therapy


Creatinine kinase


Aspartate aminotransferase


Alanine aminotransferase


Magnetic resonance imaging


Computed tomography




International normalized ratio


Cardiac MRI


Myasthenia gravis


Anti-acetylcholine receptor antibody


Anti-muscle-specific tyrosine kinase antibody


Intravenous immunoglobulin


  1. Imfimzi (durvalumab) [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

  2. Palaskas N, Lopez-Mattei J, Durand J, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9:e013757.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Zamami Y, Niimura T, Okada N, et al. Factors associated with immune checkpoint inhibitor-related myocarditis. JAMA Oncol. 2019;5(11):1635–7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Elvaz-Mohammadi S, Gonzalez-Ibarra F, Hekmatjou H, et al. Myasthenia gravis-like syndrome presenting as a component of the paraneoplastic syndrome of lung adenocarcinoma in a nonsmoker. Case Rep Oncol Med. 2014;2014:703828.

    Article  Google Scholar 

  6. Huang YT, Chen YP, Lin W, et al. Checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020;11:634.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012;8(5):427–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–34.

    Article  CAS  PubMed  Google Scholar 

  9. Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7:319.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Takamatsu K, Nakane S, Suzuki S, et al. Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. Ann Clin Transl Neurol. 2018;5(11):1421–7.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol. 2009;66(11):1334–8.

    Article  PubMed  Google Scholar 

  12. Chen JH, Lee KY, Hu CJ, Chung CC. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore). 2017;96(50):e9262.

    Article  Google Scholar 

  13. Mahmood SS, Chen CL, Shapnik N, et al. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report. Gynecol Oncol Rep. 2018;25:74–7.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


We have no acknowledgements.


Not applicable.

Author information

Authors and Affiliations



JC took the lead and wrote the initial draft and most significant edits of the manuscript. DN and LN were the primary providers at patient’s initial presentation and reviewed and helped edit the manuscript. All authors read and approved the final submission.

Corresponding author

Correspondence to Jason Cham.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient/patient’s wife for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

None reported. All authors have declared there are no financial conflicts of interest with regard to this work.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cham, J., Ng, D. & Nicholson, L. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report. J Med Case Reports 15, 278 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: